Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Sept 2007

Tran Chy-Anh, Burton Luciana, Russom Diana, Wagner Jamie R, Jensen Michael C, Forman Stephen J, DiGiusto David L

Abstract excerpt

We have developed an innovative system for ex vivo processing of patient-specific cell products to produce large numbers of T-lymphocytes in support of phase 2 adoptive immunotherapy trials for hematologic malignancies. Extensive efforts were undertaken to close the cell processing system to improve the safety profile of the process and comply with new federal regulations regarding cell and tissue processing. Our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioreactors
Share to Blood Component Removal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Cell Culture Techniques

Share to Cell Separation

Share to Immunotherapy, Adoptive

Share to Lymphocyte Culture Test, Mixed

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 17667528
DOI: 10.1097/CJI.0b013e318052e1f4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.PMID 17667528Read ↗

A closed, autologous bioprocess optimized for TCR-T cell therapiesSemantic proximity Read ↗

Reproducible and Efficient Phenotyping for Cell Therapy Manufacturing Using the Accellix Automated Flow Cytometer Platform.Semantic proximity Read ↗

High-density microbioreactor process designed for automated point-of-care manufacturing of CAR T cellsSemantic proximity Read ↗

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.Semantic proximity Read ↗

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune DiseasesSemantic proximity Read ↗

Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.Semantic proximity Read ↗

Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Semantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.Semantic proximity Read ↗

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read ↗

Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell outputSemantic proximity Read ↗

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blastsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.